Document:

EX-10.4

 Certain confidential information contained in this document, marked by [**], has been
omitted because 
 SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type

 that SOPHiA customarily and actually treats as private or confidential. 

 
 

 
 Exhibit 10.4 

AGREEMENT FOR THE CO-MARKETING OF 

PRODUCTS AND SERVICES 
  

 
  

			
	BETWEEN:	  	 AGILENT TECHNOLOGIES, INC., a company organized under the laws of Delaware, with registered offices at [**]

 
 (hereinafter referred to as “Agilent”)

		
	AND:	  	 SOPHiA GENETICS S.A., a company organized under the laws of Switzerland, with registered offices at Rue du Centre 172, CH-1025 Saint-Sulpice, Switzerland,
  
 (hereinafter
referred to as “SOPHiA”)
  
 Agilent and SOPHiA may hereinafter jointly
also be referred to as the “Parties” and each individually as a “Party”

  
  

WHEREAS SOPHiA seeks to develop algorithms to analyse data associated with Agilent gene panels and sell access to its platform to interpret this data;

 WHEREAS Agilent commercializes certain products, such as, without limitation, next-generation sequencing reagent kits, gene panels and equipment
related to the sequencing of biological samples, which it produces, manufactures and sells; 
 WHEREAS the SOPHiA Products (as defined hereinafter)
and the Agilent Products (as also defined hereinafter) are desired to be adapted and made complementary of one another; 
 WHEREAS SOPHiA and Agilent
desire to provide for marketing and sale of their products to current and prospective customers (with each party selling its own products to customers), under the terms and conditions of this present
co-marketing agreement (the “Agreement”); 
 WHEREAS the Parties anticipate that such
coordinated activities will include not only marketing and sales activities, but also related support services, and potentially the development of certain intellectual property; 

NOW, THEREFORE, the Parties agree and covenant as follows: 
  

	1.	 DEFINITIONS 

 

	1.1.	 The following terms shall have the following meaning: 

“Affiliates” means any entity controlled by, controlling, or under control with, SOPHiA or Agilent, as the case may be, and
“Control” and its derivates shall mean control by majority ownership of, or the ability to direct the disposition or exercise of voting rights of, the voting and capital stock or ownership interest of the entity in question. 

“Agilent Complementary Offering Product” means the Agilent Product identified in Schedule 2. 

“Agilent Product Data” means the data and information to be transferred from Agilent to SOPHiA hereunder as further described
in Schedule 4. 

 

 
 “Agilent Products” means those products that are manufactured, produced and sold by
Agilent as identified in Schedule 2. 
 “Agilent Trademarks” means the registered trademarks and trade names of Agilent, and
any registration or applications in the Territory in regard thereto and any trademarks Agilent or its Affiliates subsequently add thereto by mutual agreement of the Parties. 

“Agilent Confidential Information” means all confidential information of Agilent or its Affiliates or their respective
customers, which are either marked confidential or which SOPHiA should reasonably expect are confidential or proprietary, including, without limitation, technical data, designs, specifications, methods, processes, systems, test reports, protocols,
sources of supply and/or marketing data. 
 “Background Intellectual Property” means any intellectual property and
associated legal rights therein of either or both Parties developed before or independent of this Agreement, including inventions, patent applications, patents, copyrights, know-how, trademarks, trade secrets
and proprietary information, including but not limited to, technical data and source code. 
 “Complementary Offering
Product” means as applicable the SOPHiA Complementary Offering Product or Agilent Complementary Offering Product. 

“Complementary Offering” means the assemblage of SOPHiA Products and Agilent Products
co-marketed by the Parties as part of this Agreement. It is understood that, the purchaser shall purchase the SOPHiA Products directly from SOPHiA and the Agilent Products directly from Agilent. 

“Confidential Information” means collectively Agilent Confidential Information and SOPHiA Confidential Information. 

“GDPR” means General Data Protection Regulation 2016/679. 

“Jointly Developed Intellectual Property” means intellectual property arising from performance pursuant to this Agreement that
each Party contributed substantially to the development of, concerning components, methods, processes or algorithms related to either SOPHiA Products or Agilent Products. 

“Patents” means patents, patent applications (including provisional patent applications) and any issued or pending
divisionals, continuations, continuations-in-part, re-issues, re-examinations, renewals
or extensions thereof and any foreign counterpart of any of such patents. 
 “Personal Data” means any information relating
to an identified or identifiable natural person (‘data subject’); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number,
location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person. 

“Processing” (and its conjugates, including without limitation “Process”) shall mean any operation or set of
operations that is performed upon Personal Data, including without limitation collection, recording, retention, alteration, use, disclosure, access, transfer, or destruction. 

“Solely Developed Intellectual Property” means intellectual property arising from performance pursuant to this Agreement and
developed solely by one Party without any substantial contribution of the other Party. 
  

  
 Page 2 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats
as 
 private or confidential. 

 

 
  

 “SOPHiA Complementary Offering Product” means the SOPHiA Product identified
in Schedule 1. 
 “SOPHiA Product Data” means the data and information about SOPHiA Products to be transferred to Agilent
hereunder as described in Schedule 5. 
 “SOPHiA Products” means the Products that are manufactured, developed, produced and
sold by SOPHiA as identified in Schedule 1. 
 “SOPHiA Trademarks” means the registered trademarks and trade names of
SOPHiA, and any registration or applications in the Territory in regard thereto and any trademarks SOPHiA or its Affiliates subsequently add thereto by mutual agreement of the Parties. 

“SOPHiA Confidential Information” means all confidential information of SOPHiA or its Affiliates or their respective
customers, which are either marked confidential or which Agilent should reasonably expect are confidential or proprietary, including, without limitation, technical data, designs, specifications, methods, processes, systems, test reports, protocols,
sources of supply, and/or marketing data. 
 “Term” and “Initial Term” means the term and initial term
indicated in Section 12, below. 
 “Territory” means the countries and locations indicated in Schedule 3, hereto. 

“Trademark” means as applicable the SOPHiA Trademark or Agilent Trademark. 

 

	2.	 DEVELOPMENT ACTIVITIES 

 

	2.1.	 Transfer of Agilent Data. Reasonably promptly after execution of this Agreement, Agilent shall transfer
the Agilent Product Data to SOPHiA. Agilent Product Data shall be deemed Agilent Confidential Information whether or not marked as such. SOPHiA shall use Agilent Product Data solely for purposes of developing the SOPHiA Complementary Offering
Product and shall not use Agilent Product Data for any other purpose. 

  

	3.	 INTELLECTUAL PROPERTY 

 

	3.1	 All right, title and interest in and to Solely Developed Intellectual Property shall be owned by the Party that
developed such Intellectual Property. 

  

	3.2	 All right, title and interest in and to Jointly Developed Intellectual Property shall be jointly owned by the
Parties. SOPHiA shall have the right to use Jointly Developed Intellectual Property in connection with the development and commercialization of algorithms and software for analysis of gene panels and shall not use the Jointly Developed Intellectual
Property for any other purpose. Agilent shall have the right to use Jointly Developed Intellectual Property in connection with the development, analysis, and commercialization of gene panels and shall not use the Jointly Developed Intellectual
Property for any other purpose. Neither Party shall independently file any patent, trademark, or copyright applications concerning Jointly Developed Intellectual Property without the knowledge and cooperation of the other Party. In the event that
either Party desires to obtain intellectual property protection concerning Joint Intellectual Property, such Party will notify the other party in writing and such Joint Intellectual Property shall be subject to a separate agreement between the
Parties regarding protection costs, use and the rights related thereto. For the purpose of clarity, any algorithm developed by SOPHiA as part of this Agreement without a substantial contribution of Agilent shall not be construed as Jointly Developed
Intellectual Property, but shall constitute SOPHiA’s Solely Developed Intellectual Property. 

  
 Page 3 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	3.3	 Promotional, marketing or product-related materials and documentation
co-developed by the Parties under the scope of this Agreement shall be Jointly Developed Intellectual Property. During the Term of this Agreement, each of SOPHiA and Agilent (and their respective Affiliates)
may use such promotional, marketing or product-related materials and documentation solely for the purposes and commercial activities set forth in this Agreement. 

 

	3.4	 This Agreement does not grant and shall not be construed as implying that either Party shall have the right to
use Background Intellectual Property of the other Party except as otherwise provided in this Agreement and neither Party will as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other
Party. 

  

	3.5	 As part of this Agreement, SOPHiA may communicate certain improvements, alterations, comments, feedback or
suggestions to Agilent relating to Agilent Products (collectively, the “SOPHiA Feedback”) and Agilent may communicate certain improvements, alterations, comments, feedback or suggestions to SOPHiA relating to SOPHiA Products
(collectively, the “Agilent Feedback”). SOPHiA Feedback shall be deemed Agilent Confidential Information hereunder and shall be owned solely by Agilent. Agilent Feedback shall be deemed SOPHiA Confidential Information hereunder and
shall be owned solely by SOPHiA. 

  

	3.6	 Except as specifically set forth in this Agreement, neither Party’s intellectual property shall be
licensed, assigned or otherwise transferred to the other Party. 

  

	4.	 CO-MARKETING ACTIVITIES 

 

	4.1.	 Promotion of Agilent Products. In connection with the promotion by SOPHiA of the Agilent Products,
Agilent hereby authorizes SOPHiA, its Affiliates, authorized distributors and resellers to promote Agilent Products in accordance with this Agreement, including, without limitation, providing marketing material, specifications (as indicated from
time to time by Agilent) and otherwise mention the Agilent Products to its network of existing and new customers. 

  

	4.2.	 Promotion of SOPHiA Products. In connection with the promotion by Agilent of the SOPHiA Products, SOPHiA
hereby authorizes Agilent, its Affiliates, authorized distributors and resellers to promote SOPHiA Products in accordance with this Agreement, including, without limitation, providing marketing material, specifications (as indicated from time to
time by SOPHiA) and otherwise mention the SOPHiA Products to its network of existing and new customers. 

  

	4.3.	 Coordinated Marketing Activities. The Parties shall mutually agree on the marketing activities to be
conducted with respect to the Complementary Offering. SOPHiA and Agilent, at their own respective costs and expense, shall use reasonable efforts to perform such marketing activities with the agreed upon timelines. Each Party is responsible for
(i) printing, publishing and distributing at its own cost and expense, any such marketing materials, and (ii) training of its respective relevant sales and technical personnel in connection with the joint marketing and promotion of the
SOPHiA Products and Agilent Products. For the avoidance of doubt all marketing materials (such as but not limited to marketing brochures and websites) shall be approved in writing by both Parties. Prior to use, marketing materials shall be sent to
the other Party for approval, which shall not be unreasonably withheld. 

  

	4.4.	 Either Party may, upon prior written consent of the other Party, issue one or more press releases relating to
this Agreement and to the Products herein. The text of any such press release shall be mutually agreed by both Parties and shall be subject to both Parties’ written consent before each time such release is used or published. Except for the
information disclosed in such press release, neither Party shall reveal the terms of this Agreement in any publicity or advertising without the prior written approval of the other Party. Each Party shall have the right to identify the other Party
and to disclose the terms of this agreement to the limited extend required by applicable laws and regulations, provided that the disclosing Party takes reasonable and lawful actions to minimize the degree of such disclosure. 

  
 Page 4 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	5.	 COORDINATED SALES ACTIVITIES 

 

	5.1.	 Sales promotion. Within [**] after the date hereof, SOPHiA and Agilent shall each designate to the other
in writing a key sales contact person (the “Contact Person”) for coordinating the marketing activities, and on a regular basis thereafter such Contact Persons of the parties shall, subject to all applicable laws share with each
other information regarding customers or potential customers (“Leads”) of SOPHiA and Agilent for the sole purpose of promoting sales of the Complementary Offering, it being understood that: 

 

	 	5.1.1.	 The Contact Person for each Party may assign such Lead to a specified salesperson from such Party for follow-up with a designated salesperson of the other Party hereto. Any joint sales visit to any Lead shall be coordinated between the designated salesperson of SOPHiA and Agilent, and any travel costs or other
expenses in connection with such sales visit shall be borne by the respective party. 

  

	 	5.1.2.	 The designated salesperson(s) shall promptly report to the Contact Person of the relevant Contact Person of
SOPHiA and Agilent, respectively, the results of any such joint sales visit and the contemplated next steps. 

  

	 	5.1.3.	 Leads may be referred between either Party at the sole discretion of referring Party. However, referrals for
Leads that will benefit the purposes of this agreement shall not be unreasonably withheld by either Party. 

  

	 	5.1.4.	 Lead information may be used solely for the purposes of promoting Sales of the Complementary Offering and for
no other purpose. 

  

	 	5.1.5.	 Except as set forth herein, neither Party shall provide customer information to the other Party.

  

	5.2.	 Sales. Except as contemplated pursuant to any other agreement pertaining to the same subject-matter,
each of SOPHiA and Agilent shall sell their respective products to any Lead in separate sales transactions between SOPHiA and Agilent, respectively, on the one hand, and the Lead, on the other hand, and each of SOPHiA and Agilent shall invoice the
Lead separately. 

  

	5.3.	 After sales service. SOPHiA shall be responsible for support requests from Leads with regards to the
SOPHiA Product. Agilent shall be responsible for support requests from Leads with regards to the Agilent Product. If a Lead submits a support request to the incorrect party, the other party shall forward such request to the Contact Person for the
other party within [**]. 

  

	5.4.	 Other products. Each Party hereto acknowledges and agrees that the cooperative efforts hereunder are non-exclusive with regards to other products and/or services developed, produced, manufactured or sold by them respectively and not referenced to in this Agreement, and neither Party has the duty or obligations to
refer any particular Lead, even if within the Territory, to the other Party. In addition, each Party acknowledges and agrees that the other Party hereto may promote, market, and sell its respective Products with the products of competitors of the
other Party hereto, provided, however, that such Party does not breach its obligations under this Agreement (such as, without limitation, subsection 4.1 and Section 9). In addition, each Party acknowledges and agrees that the other Party may
independently develop or acquire products that use or contain technology, ideas, concepts, know-how or techniques similar to those of the other Party’s hereunder and commercialize such product, provided,
however, that such products are developed without the use of any Confidential Information of the other Party. 

  
 Page 5 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	5.5.	 Pricing, payment and relationship with Leads. It is understood that even if the Complementary Offering
is marketed jointly by the Parties, the individual components of the Complementary Offering, constituting of the SOPHiA Product and Agilent Product(s), shall be sold individually. To that extent, the following conditions shall apply:

  

	 	5.5.1.	 The Parties shall discuss in good faith when one of them becomes aware of a new Lead. Each Party shall
determine in its sole discretion, the pricing for its applicable product for such Lead. The Parties shall not coordinate pricing for the Complementary Offering and shall not provide pricing to the other except for standard list prices and publicly
available then-current market prices. 

  

	 	5.5.2.	 Upon acceptance of an offer by a Lead, each Party shall provide to the Lead a standard commercial agreement for
their respective parts in the Products. Each Party shall be free to discuss its standard terms and conditions applicable to the sale of its Complementary Offering Product (such as terms of use, licenses or terms of sale) with such Lead. Such
discussions shall be at each Party’s entire discretion, and a Party may elect to back out of an agreement if the terms requested by the Lead are not acceptable. 

 

	 	5.5.3.	 Each Party shall provide its respective product of the Complementary Offering to such Lead solely if the Lead
has agreed to purchase both the SOPHiA Complementary Offering Product and the Agilent Complementary Offering Product, and the duration for the provision of the SOPHiA Complementary Offering Product and the Agilent Complementary Offering Product are
the same. 

  

	 	5.5.4.	 Once the Lead has agreed to commercial terms with each Party, the Lead shall order SOPHiA Products from SOPHiA,
and Agilent Products from Agilent. 

  

	 	5.5.5.	 Each Party shall invoice the Lead in accordance with their general terms and conditions, as indicated in their
respective commercial agreements, and the Lead shall pay individually each Party for the SOPHiA Product and the Agilent Product, respectively. 

  

	 	5.5.6.	 Each Party agrees that during the term of the commercial agreement for such Lead, it shall not, directly or
indirectly, dislodge or influence the Lead to purchase a product or service that would replace the Complementary Offering. 

  

	 	5.5.7.	 Should a Lead or a Party terminate its commercial agreement with one of the Parties for either the SOPHiA
Products or the Agilent Products, the Party that was terminated shall provide notice to the other Party. 

  

	 	5.5.8.	 After the Parties consummate sale of their respective Product to the Lead, the Lead is a customer of each
respective Parties and each Party is free to use the information required to provide services to such Lead consistent with such Party’s customer information policies. 

 

	6.	 DATA PRIVACY 

 

	6.1.	 Independent Controllers. With respect to Lead Personal Data, Agilent solely determines the purposes and
means of Agilent’s Processing of such Personal Data. Similarly, SOPHiA solely determines the purposes and means of SOPHiA’s Processing of such Personal Data. Therefore, the Parties agree that each is an independent controller of such
Personal Data. Each Party undertakes to comply with the following obligations with respect to such Personal Data: 

  

  
 Page 6 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	 	6.1.1.	 Each Party shall ensure that it has all necessary consents or other lawful grounds, and notices in place to
enable lawful transfer of Personal Data to the other Party and for the other Party to Process such Personal Data in accordance with this Agreement. Each Party warrants and represents that it is and will at all relevant times remain duly and
effectively authorized to provide the Personal Data to the other Party. In particular, each Party warrants and represents that (i) it has obtained and will maintain all necessary rights and authorization for such communication and processing by
the other Party in accordance with the Agreement, (ii) it has informed the data subject about the processing in accordance with this Agreement and (iii) such Personal Data are adequate, relevant, limited to the purposes of the Personal
Data processing in accordance with this Agreement, accurate and up-to-date. Each Party shall provide solely that Personal Data that is relevant for the purposes of this
Agreement. 

  

	 	6.1.2.	 Each Party shall Process Personal Data in compliance with all applicable laws, including data protection laws,
including GDPR. 

  

	 	6.1.3.	 Technical and organizational security measures that are appropriate to the risks, such as against accidental or
unlawful destruction or accidental loss, alteration, unauthorized disclosure or access, presented by the processing must be taken by each Party. 

  

	 	6.1.4.	 In the event of any actual or suspected security incident affecting Personal Data provided by the other Party,
the Party in receipt of such Personal Data shall notify the providing Party via e-mail within [**] of discovering such incident: 

For Agilent: to [**]. 
 For SOPHiA
to [**] 
  

	 	6.1.5.	 Each Party shall notify the other Party promptly, and in any event within [**] of receipt of any correspondence
from: (I) a data protection regulator in relation to Personal Data provided hereunder, or (II) a request or notice from a data subject exercising his rights under the data protection laws including to access, rectify or delete Personal
Data provided hereunder. 

  

	6.2.	 Categories of Personal Data processed. Each Party may process (i) Agilent Product Data, which may
contain Personal Data, which Personal Data is described in Exhibit 4, (ii) SOPHiA Product Data, which may contain Personal Data, which Personal Data is described in Exhibit 5, (iii) Lead Personal Data and (iv) Personal Data of any member of the
personnel of each Party or any Affiliates (i.e. contact details). 

  

	6.3.	 Recipient of Personal Data. The access of the Personal Data set forth in Section 6.2 is limited to
duly authorized members of the personnel of each Party, its Affiliates and its processors. 

  

	6.4.	 Transfer of Personal Data. Each Party shall not transfer such Personal Data to countries outside the
European Union without adequate level of protection and without appropriate safeguards as defined by the data protection laws and in particular by the GDPR. It is understood that the Parties shall sign the European Union Standard Contractual
Clauses. 

  

	6.5.	 Purposes of the processing. The aforementioned Personal Data will be processed by each Party to:

  

	 	•	 	 perform this Agreement, with regard to processing operations intended to carry out operations relating to the follow-up of the contractual relationship and to perform the contractual obligations of each Party (services, invoices, accounting, development of the agreed algorithm), 

 

  
 Page 7 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	 	•	 	 respect the legitimate interest pursued by each Party, with regard to processing operations for the purpose of
improving and/or developing products and/or services of each Party, or compiling statistics, or conducting scientific and/or medical research, or selecting suppliers, or promoting products and services of each Party, to the extent such activities
are consistent with the notice provided to the data subject; 

  

	 	•	 	 comply with legal obligations applicable to each Party, with regard to processing for invoicing and accounting
purposes or the management of requests for the exercise of rights of access, rectification, limitation, restriction, opposition, erasure and portability of the data subject. 

 

	6.6.	 Period of processing. The aforementioned Personal Data is subject to processing and shall be kept by
each Party in a form which permits identification of data subjects for no longer than is necessary for the purposes for which the aforementioned Personal Data are processed. In this respect, such Personal Data shall be kept for the duration of the
Agreement, without prejudice to any retention obligations or limitation periods; provided, however, with respect to Lead Personal Data where a sale was made, a Party may retain such information in accordance with Section 5.5.8.

  

	6.7.	 Rights of data subject. The data subjects may have a permanent right of access, rectification,
limitation, restriction, opposition, erasure and portability to all their Personal Data, in accordance with the data protection laws. They also may have a right to lodge a complaint with a Supervisory Authority, if they consider that any processing
of their Personal Data infringes the requirements of data protection laws. They may at any time make a request by sending an e-mail to SOPHiA GENETICS to: [**] and to Agilent to [**]. For reasons of security
and proof and to avoid any fraudulent request, this request must be accompanied by identity document. 

  

	6.8.	 Each Party understands that the other Party will collect Personal Data such as the Party’s personnel names
and contact details on the basis of such other Party’s legitimate interests for the purpose of the efficient operation of the Agreement. Each Party will store and use the Personal Data in accordance with their respective security and privacy
policies. 

 SOPHiA shall inform its affected personnel that Agilent will store and use SOPHiA’s personnel names and
contact details in accordance with Agilent’s Privacy Statement, available at www.agilent.com/go/privacy. 
  

	7.	 TRADEMARKS 

 

	7.1.	 Each Party will provide the other Party with electronic files containing the trademarks, logos and trade names
of such Party for the limited purposes provided in Section 4 hereinabove. Only those trademarks, logos and tradenames required for the limited purpose of this Agreement shall be so provided.  

 

	7.2.	 By SOPHiA. SOPHiA hereby grants to Agilent and its Affiliates, during the Term hereof, a limited,
non-sublicensable, non-transferable (except as set forth in subsection 13) royalty-free, non-exclusive right and license to use the SOPHiA Trademarks and SOPHiA Confidential Information in the Territory solely
for the promotion and marketing of the SOPHiA Products as part of the joint marketing efforts contemplated herein, it being expressly understood that Agilent and its Affiliates shall discontinue the use thereof upon expiration or termination of this
Agreement. 

  

	7.3.	 By Agilent. Agilent hereby grants to SOPHiA and its Affiliates, during the Term hereof, a limited,
non-sublicensable, non-transferable (except as set forth in subsection 13) royalty-free, non-exclusive right and license to use the Agilent Trademarks and Agilent
Confidential Information in the Territory solely for the promotion and marketing of the Agilent Products as part of the joint marketing efforts contemplated herein, it being expressly understood that SOPHiA and its Affiliates shall discontinue the
use thereof upon expiration or termination of this Agreement. 

  

  
 Page 8 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	7.4.	 Ownership of each Party’s marks. Each Party acknowledges and agrees that it has no right,
title or interest in the other Party’s marks, except the limited use of the same as provided herein or as otherwise provided in writing by the Parties, and that nothing in this Agreement shall be construed as an assignment or grant to any
right, title or interest in the other Party’s marks. All use of marks owned by one Party (“Licensor”) by the other Party (“Licensee”) and goodwill created therein shall inure to the benefit of the Party owning
the marks. The Licensor of the Trademark shall have the sole and exclusive right to enforce any rights in its Trademarks. Each Party shall assist the other Party in the maintenance and protection of the other Party’s marks and any registrations
therefor by taking such acts and executing such documents, at the other Party’s expense, as the other Party reasonably requires to protect or register its marks anywhere in the world. 

 

	7.5.	 Other than the express licenses granted herein with respect to each Licensor’s Trademarks, nothing herein
will grant to Licensee any other right, title or interest in Licensor’s Trademarks. The Licensor shall have the sole and exclusive right to enforce any rights in Licensor’s Trademarks. 

 

	7.6.	 Each use of a Party’s Trademarks by the other Party will be accompanied by a legend specifying that such
Trademarks are trademarks of the other Party, and will be in accordance with the other Party’s then-current trademark usage policies as provided in writing from time to time. Any specific use by either Party (the “First Party”) of the
other Party’s trademarks or trade names in any advertising copy, brochures, or literature or in promotional material, or on the letterhead of the First Party, shall be submitted in advance for approval by such other Party.

  

	8.	 WARRANTIES 

 

	8.1.	 Mutual Warranties. Each Party represents and warrants that it has the right and authority to enter into
this Agreement and to provide the rights granted hereunder, and that by entering into this Agreement, it will not violate, conflict with or cause a material default under any other contract, agreement, indenture, decree, judgment, undertaking,
conveyance, lien or encumbrance to which it is a party or by which it or any of its property is or may become subject or bound. 

  

	8.2.	 Compliance with Laws. Each Party represents and warrants that no consent, approval or authorization of
or designation, declaration or filing with any governmental authority is required in connection with the valid execution, delivery, and performance of this Agreement. Each Party shall, at its own expense, comply with all laws, regulations and other
legal requirements that apply to it and this Agreement, including copyright, privacy and communications decency laws. All products marketed under this Agreement shall be marketed solely for research use only and each Party agrees to comply with all
applicable laws regarding marketing of such Products. Each Party shall comply with the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “Act”) and the U.S. Anti-Kickback Statute (42 U.S.C.
1320a-7b) and neither Party, nor any of its directors, officers, employees, or agents will make or offer to make any payment or gift directly or indirectly to any third party, including any employee, officer,
or representative of any governmental entity or instrumentality or to any foreign political party, or candidate, save that gifts of a nominal value which comply with all applicable laws and regulations, and are not given to influence any commercial
or official decision may be permitted. 

  

	8.3.	 Conformity with published specifications. Complementary Offering Products sold by a Party to end-user shall comply with its published specification, as may be revised from time to time by such Party. However, Agilent shall give no warranties on SOPHiA Products and SOPHiA shall give no warranties on Agilent
Products. 

  

	8.4.	 DISCLAIMER. EACH OF SOPHIA AND AGILENT DISCLAIM ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED,
INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IN REGARD TO THE SOPHIA PRODUCT AND THE AGILENT PRODUCTS, RESPECTIVELY, AND THE RESPECTIVE SERVICES OF EACH. 

  
 Page 9 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	9.	 INSURANCE 

 

	9.1.	 Coverage. During the Term, and for a period of [**] thereafter, each Party shall, at its own expense,
maintain and carry in full force and effect, at least the following types and amounts of insurance coverage, to be issued by an insurance company with an acceptable rating: (a) commercial general liability with limits [**] in the aggregate,
including bodily injury and property damage and product and advertising liability, which policy shall cover the activities of the Party under this Agreement; (b) Worker’s compensation insurance as required under applicable law; and
(c) other such insurance as required under applicable laws and regulations. 

  

	9.2.	 Certificates. Upon request, each Party shall provide the other with copies of the certificates of
insurance for all insurance coverage required under subsection 6.1, and shall not do anything to invalidate such insurance. This subsection shall not be construed as waiving, restricting or limiting the liability of either Party for any obligations
imposed under this Agreement (such as the obligation to indemnify, defend and hold harmless the other Party under this Agreement). 

  

	10.	 INDEMNIFICATION AND LIMITATION OF LIABILITY 

 

	10.1.	 Indemnification. Each Party (the indemnifying party) agrees to indemnify and hold the other Party (the
indemnified party) harmless from all claims, losses, expenses, fees including reasonable attorney’s fees (save for Europe where attorney’s fees will be excluded but local legislation will be followed), costs, and judgments to the extent
resulting from any third party claim that may be asserted against the indemnified Party that results from (a) a direct result of the Party’s gross negligence, willful misconduct or malfeasance, (b) breaches of this Agreement by the
indemnifying party, or (c) any claim alleging that the other party’s use of a licensing party’s Trademarks in accordance with this Agreement infringes upon any intellectual property right of a third party, or (d) a party’s
Products infringes any third party intellectual property rights. 

  

	10.2.	 The indemnified party shall promptly notify the indemnifying party of any such claim in writing and the
indemnifying party shall have the right to control the defense, including any settlement thereof; provided that the indemnifying party shall not settle any such claim without indemnified party’s prior written consent, not to be unreasonably
withheld. The indemnified party shall reasonably cooperate with the indemnifying party in the defense of any such claim. 

  

	10.3.	 No consequential damages. NEITHER PARTY HERETO SHALL BE LIABLE FOR SPECIAL, INCIDENTAL, PUNITIVE OR
CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION IS
INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY OR TO LIMIT A PARTY’S LIABILITY FOR BREACHES OF ITS CONFIDENTIALITY OBLIGATIONS. 

 

	11.	 CONFIDENTIALITY 

 

	11.1.	 The Parties shall keep confidential all Confidential Information of the other Party, provided that the
receiving Party is entitled to disclose to its Affiliates and employees and bona fide third Parties (which, in the case of the SOPHiA, means its authorized end users, resellers and distributors and in the case of Agilent, includes Agilent’s
authorized end users, distributors and resellers) Confidential Information only as far as is necessary to enjoy the rights granted or perform the obligations herein. The Parties shall also ensure that all Affiliates, employees and third Parties
undertake the same or similar confidentiality obligations. The preceding undertakings shall not apply to information given that the receiving Party can show such information (i) is available in the public domain or is publicly accessible
through no fault of the receiving Party, (ii) is obtained by the receiving Party from a third party who had the legal right to disclose the same to the receiving Party without obligation of confidentiality, (iii) is in the receiving
Party’s prior possession without obligation of confidentiality, as evidenced by conclusive evidence or (iii) is independently developed by the receiving Party without reference to or use of Confidential Information as evidenced by
conclusive evidence. 

  

  
 Page 10 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	11.2.	 In the event that the receiving Party is required by applicable laws, regulations or court order to disclose
any of the disclosing Party’s Confidential Information, the receiving Party shall have the right to disclose any of such Confidential Information; provided that (a) it shall give the disclosing Party immediate notice thereof so that the
disclosing Party may seek an appropriate protective order, and (b) it discloses only that portion of such Confidential Information that it is required to disclose. The receiving Party shall reasonably cooperate with the disclosing Party in its
efforts to seek such a protective order. 

  

	11.3.	 Upon termination or expiration of this Agreement or at the disclosing Party’s request, the receiving Party
shall return or destroy all documentary, electronic or other tangible forms of the disclosing Party’s Confidential Information, including without limitation any and all copies thereof. Any party conducting a destruction of the aforementioned
information shall provide adequate evidence of the information’s destruction. Notwithstanding the foregoing, the receiving Party may retain one copy of the other Party’s Confidential Information solely to monitor its obligations hereunder.

  

	12.	 FORCE MAJEURE 

Neither Party shall be held responsible to the other Party for any default or delay in the execution of its obligations caused by circumstances
beyond its control. Without limiting the generality of the foregoing, natural disasters, strikes, fires, war and insurrections and actions or government or regulatory bodies, which prevent a Party from performing under the Agreement shall be deemed
to constitute force majeure, provided however, that the Party that is excused from performance takes all measures necessary to prevent, control or limit the effect of the force majeure so that performance may resume as soon as possible. 

 

	13.	 RELATIONSHIP OF THE PARTIES 

Each Party is an independent contractor, and this Agreement shall not be construed to create any association, partnership, joint venture,
employee, or agency relationship between SOPHiA and Agilent for any purpose. Each Party has no authority (and shall not hold itself out as having authority) to bind the other Party and each Party shall not make any agreements or representations on
the other Party’s behalf without said other Party’s prior written consent. 
  

	14.	 TERM AND TERMINATION 

 

	14.1.	 Term.  

  

	 	a.	 Initial Term. The initial term of this agreement begins on the effective date and will continue for two
(2) years, unless terminated earlier (“Initial Term”); 

  

	 	b.	 Renewal Term by notice. Parties may renew this agreement for successive renewal terms of one
(1) year each (“Renewal Term”); 

 “Term” means the Initial Term together with any Renewal
Term(s). 
  

	14.2.	 Termination. Notwithstanding any other provision of this agreement to the contrary, this agreement, or
any extension thereof, may be terminated prior to the expiration of the term by each of the parties 

  

	 	(i)	 Upon [**] prior written notice to the other Party. 

 

	 	(ii)	 Immediately upon written notice to the other Party where the
non-terminating Party is found in material breach of this Agreement and such breach remains uncured for a duration of [**] from the date on which said Party was notified of the breach in writing by the
terminating Party. 

  
 Page 11 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

	14.3.	 Consequences of termination. Upon termination or expiration of this Agreement, the following shall be
put in place between the Parties: 

  

	 	14.3.1.	 Termination shall have no consequences upon the obligation of each Party to comply with purchase orders,
contracts and other agreements entered into prior to the effective date of such termination of this Agreement and each Party shall have the right to fulfill any such obligations entered into prior to termination, including, without limitation,
long-term commitments as appears from their respective contractual arrangements with Leads. The termination of this Agreement shall not terminate the liability of the breaching of defaulting Party, if any, resulting from such breach or default and
indemnifiable under Section 10. 

  

	 	14.3.2.	 The Parties shall wind down operations of the Complementary Offering in a way that affects as little as
possible each Party’s business operations and any Lead or customer’s operations over a course of [**] further to the termination or expiration date. To that end, it is agreed that any agreement concluded between a Party and a Lead on the
Complementary Offering shall remain in full force and effect up until the shorter of (i) the non-renewal of the commercial contract for the Complementary Offering (which should be the same for each
Product), (ii) the Lead elects to terminate the Agreement, or (c) upon mutual agreement of both Parties and the Lead. This subparagraph shall include multi-year agreements or firm commitments undertook by a Party. Each Party shall continue to
support the Complementary Offering for the duration of the customer agreement with Leads. 

  

	 	14.3.3.	 The following Sections will survive any expiration or termination of this Agreement: 3, 6, 7.4, 7.5, 10, 11,
14.3 and 15. Notwithstanding the foregoing, the expiration or termination of this Agreement will not relieve the Parties of any liability or obligation that accrued prior to such expiration or termination. 

 

	 	14.3.4.	 Upon expiration or termination of this Agreement, each party will cease the display and use of the Trademarks
and Products of the other Party and will not use or display the Trademarks or Products of the other Party except as permitted by applicable law. 

  

	14.4.	 Neither Party will be liable to pay compensation in money nor in kind or any other form for terminating the
agreement according to article 12.2. 

  

	15.	 MISCELLANEOUS 

 

	15.1.	 Notices. Should a written notice be required under the terms of this Agreement, it shall be sent to the
following address, by recommended mail: 

 If to Agilent: 

Agilent Technologies, Inc. 
 [**]

 With copy to: 
 Agilent
Technologies, Inc. 
 [**] 
 If
to SOPHiA: 
 SOPHiA GENETICS SA 

Rue du Centre 172 

  
 Page 12 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 1025 St-Sulpice 

Switzerland 
 Attention: [**] 

 

	15.2.	 Modification and waiver. This Agreement may only be modified or amended by written agreement of both
Parties. No amendment or waiver of terms of this Agreement is effective unless it is in writing and signed by both Parties. 

  

	15.3.	 Waiver of Contractual Right. The failure of either Party to enforce any provision of this Agreement
shall not be construed as a waiver of limitation of that Party’s right to subsequently enforce and compel strict compliance with every provision of this Agreement. 

 

	15.4.	 Governing law. This Agreement is made pursuant to, and shall be construed and enforced exclusively in
accordance with, the internal laws of the state of New York, without giving effect to otherwise applicable principles of conflicts of law. The United Nations Convention on Contracts for the International Sales of Goods is excluded in its entirety.
The Parties hereby accept the jurisdiction of the federal courts of the state of New York, USA to resolve any dispute arising from this Agreement. 

  

	15.5.	 Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns and designees; provided, however, that neither party shall have the right to transfer, assign or delegate its rights or obligations under this Agreement or any portion thereof without the prior
written consent of an authorized representative of the other party hereto (except that (i) either party may assign this Agreement without such consent to an Affiliate and (ii) either party may assign this Agreement without such consent to
an entity which acquires all or substantially all of the assets of such party to which this Agreement relates). 

  

	15.6.	 Interpretation. This Agreement constitutes the entire agreement and understanding between the Parties
concerning the subject matter hereof and supersedes all prior communications, negotiations and agreements concerning the subject matter. 

  

	15.7.	 Counterparts. This Agreement may be signed in counterparts with the same effect as if the Parties had
all signed the same document. All counterparts shall be construed together and constitute one and the same document. 

  

	15.8.	 Export Control. The Parties agree to comply with all applicable United States laws and regulations that
may govern the export of Products or information regarding the Products, including the Export Administration Act of 1979, as amended, any successor legislation, and the Export Administration Regulations issued by the Department of Commerce.

  

	15.9.	 No Third Party Beneficiaries. Except as expressly set forth herein, no provision of this Agreement is
intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any person or entity other than the Parties hereto and their respective successors and assigns. 

  
 Page 13 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 IN WITNESS WHEREOF, the said Parties have hereunto set their signatures: 

 

					
	AGILENT TECHNOLOGIES, INC.	 	        	  	SOPHiA GENETICS SA
			
	 /s/ Kevin Meldrum
	 		  	 /s/ Daan Van Well

	Name: Kevin Meldrum	 		  	Name: Daan Van Well
	Title: Vice President and General Manager	 		  	Title: General Counsel
	Date: December 7, 2020	 		  	Date: December 18, 2020
			
	  
	 		  	 /s/ Kevin Puylaert

		 		  	Name: Kevin Puylaert
		 		  	Title: VP Business Development
		 		  	Date: December 18, 2020

  
 Page 14 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 SCHEDULE 1 

SOPHiA Products 
 SOPHiA
Complementary Offering Product 
 [**] 

  
 Page 15 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 SCHEDULE 2 

Agilent Products 

Agilent Complementary Offering Product 

[**] 

Non-exclusive Products 

[**] 

  
 Page 16 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 SCHEDULE 3 

Territory 
 The Territory shall include
the following: Worldwide. 

  
 Page 17 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 Schedule 4 

Agilent Product Data 
 Data generated by
Agilent and shared with SOPHiA may include the following: 
  

	 	•	 	 [**] 

  

	 	•	 	 [**] 

  

	 	•	 	 [**] 

  
 Page 18 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential. 

 

 
  

 Schedule 5 

SOPHiA Product Data 
 Data generated by
SOPHiA and shared with Agilent may include the following: 
  

	 	•	 	 [**] 

  

	 	•	 	 [**] 

  
 Page 19 of 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA 

(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as 

private or confidential.EX-10.5

 Certain confidential information contained in this document, marked by [**], has been
omitted 
 because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material 

and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. 

Exhibit 10.5 
 AMENDED
AND RESTATED 
 MANUFACTURING AND SUPPLY AGREEMENT 

“Lockdown NGS Panels” 

THIS AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of
October 9, 2018, (the “Effective Date”), between Integrated DNA Technologies a Delaware corporation located at [**] (“IDT”) and Sophia Genetics SA, and its subsidiaries and affiliates having an
office at Rue du Centre 172, CH-1025 Saint Sulpice, Switzerland, (“Sophia”). 

PREAMBLE 
 WHEREAS, the
Parties hereto originally entered into a Manufacturing and Supply Agreement signed December 17, 2015 without Exhibits, and later entered into a subsequent agreement signed March 14, 2016 with finalized Exhibits, under which IDT supplied
Sophia with certain NGS products which were limited for resale by Sophia to European customers only (collectively, the two agreements are the “Original Agreement”); and, 

WHEREAS, both Parties wish to enter into this amended and restated Agreement, which supersedes and replaces the Original Agreement, by
expanding the list of NGS products that Sophia can resell, and specifically to expand the customer base; 
 NOW, THEREFORE in consideration
of the foregoing, and for other good and valuable consideration regarding terms of a supply arrangement between IDT and Sophia the Parties agree as follows: 

ARTICLE 1 

DEFINITIONS; SUPERSEDING AGREEMENT 

Section 1.01. Definitions. All capitalized terms used in this Agreement, whether used in the singular or the plural, have the
meanings set forth in Appendix D. 
 Section 1.02. Superseding Agreement. It is the intent of the Parties, to irrevocably
replace and supersede the Original Agreement with this Agreement. The rights and obligations of the Parties are to be exclusively defined by the terms, conditions, rights, and obligations as expressed herein. All existing and future rights and
obligations of the Parties, including specifically all post termination rights and obligations, contained in the Original Agreement, are hereby null and void, In the event any term of the Original Agreement is not specifically superseded or
modified, or replaced by a corresponding term of this Agreement, it shall be construed as a deliberate omission by the parties. 

 ARTICLE 2 

SUPPLY OF COMMERCIAL PRODUCTS BY IDT TO
SOPHIA 
 Section 2.01. Manufacture and Supply. During the term of this Agreement, IDT shall manufacture and
supply Sophia with the forecasted quantities of Commercial Products that are ordered by Sophia in accordance with the Product Specifications. IDT and Sophia shall maintain a Master Specification Document for all Commercial Products manufactured
under this Agreement. 
 Section 2.02. Forecast. Sophia shall provide to IDT within [**] following the Effective Date and on a
quarterly basis thereafter, a written good faith non-binding purchasing forecast of the aggregate quantities of Commercial Products, which Sophia expects to purchase during the following twelve months. Not
later than [**] thereafter during the term of this Agreement, Sophia shall provide an updated twelve month rolling forecast of Sophia’s expected requirements for Commercial Products in compliance with the requirements set forth above. 

Section 2.03. Inventory/Capacity. IDT shall insure a sufficient inventory of all materials and manufacturing capacity needed to
manufacture Commercial Products in the forecasted quantities. 
 Section 2.04. Purchase Orders. Sophia shall issue to IDT
purchase orders and IDT will accept such purchase orders, subject to Article 6, which shall confirm the quantity of Commercial Products, the requested delivery date, and all other product information needed for the appropriate labeling and shipping
arrangements for Commercial Products. Each order shall be submitted electronically to the MT Account Specialist identified as the Sophia account representative. Upon receipt of such purchase orders, IDT shall have [**] to accept to the requested
delivery date or to reject it, and propose an alternative date of delivery. 
 Section 2.05. Additional Demand. Sophia may
submit purchase orders to IDT for quantities of Commercial Products in excess of the forecasted quantities made pursuant to 2.02 above. IDT shall use commercially reasonable efforts to fill all such orders. If IDT expects to be unable to fill the
portion of any such excess order then IDT shall notify Sophia immediately after receipt of the purchase order. 
 Section 2.06.
Supply to Affiliates. If any other Affiliate of Sophia, namely Sophia Genetics Ltd, Sophia Genetics (France), and any other future affiliate, desires to purchase Commercial Products from IDT under the terms of this Agreement, then IDT shall
accord such Affiliate all of the benefits hereof and treat such Affiliate as “Sophia” for the purposes of this Agreement, provided however that IDT reserves the right to revise pricing for any change in Product Specifications, labeling or
other services associated with an Affiliate’s use of this Agreement to purchase Commercial Products. 

  
 2 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually

 treats as private or confidential. 

 Section 2.07. Delivery to Customers of Sophia. IDT shall deliver the Commercial
Products FCA-Coralville (Incoterms) in accordance with the MSD requirements of each purchase order to each Customer of Sophia address indicated thereon. For all inventoried items, IDT shall ship the Commercial
Products within [**] of acceptance of the purchase order. The parties acknowledge that each stocking build of Commercial Products will require custom quote manufacturing lead times prior to the Commercial Products becoming available for shipment to
Customers of Sophia. 
 Section 2.08. Failure to Supply to Sophia. If during the Term of this Agreement, IDT fails to supply
Sophia’s requirements with respect to Commercial Products, Sophia may, at its discretion, upon [**] written notice to IDT either (a) require IDT to supply the undelivered conforming Commercial Products at a future date to be agreed upon by
the Parties; or (b) terminate the then current purchase order. Failure of supply occurs when IDT cannot ship the amounts of Commercial Products firmly ordered by Sophia within [**] of the forecasted “worst-case” delivery date provided
by IDT. 
 Section 2.09. Failure to Supply to Customers of Sophia. IDT shall not fail to supply customers of Sophia after
acceptance of the shipping order. If IDT anticipates that the order cannot be fulfilled, IDT will inform Sophia within [**], and IDT will supply the conforming Commercial Products no later than [**] after order date. 

Section 2.10. Title and Risk. Title and risk of loss pass to Sophia upon delivery of Commercial Products to Sophia. North American
and international freight, insurance, and other costs relating to shipping of the Commercial Products shall be IDT’s responsibility and paid directly by IDT, and itemized on Agreement Product invoices as additional charges to be paid by Sophia
to IDT. 
 ARTICLE 3 

SUPPLY OF RESEARCH PRODUCTS FROM IDT TO
SOPHIA 
 Section 3.01. Manufacture and Supply. Sophia may order Research Products using the IDT website ordering
system. IDT will not apply any Sophia-specific forecasting, ordering, manufacturing, shipping or delivery rules to Research Products. Pricing specific to Sophia for Research Products is included in Exhibit C2. 

ARTICLE 4 
 QUALITY
AND WARRANTY 
 Section 4.01. Master Specification Documents/Changes. Once finalized by mutual
agreement of the Parties, IDT shall not make any material changes to the procedures or specifications described in the Master Specification Document of any Agreement Product without the advanced notification of Sophia. A list of finalized MSDs is
attached hereto as Exhibit B and may be added to or changed with each new Agreement Product or revision of referenced MSD upon written agreement by both parties. Alterations in quality control procedures and the Product Specifications may be
introduced from time to time by prior written agreement between IDT and Sophia. 

  
 3 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 4.02. Certificates of Manufacturing Compliance. IDT shall provide for
each Agreement Product delivered a signed certificate of manufacturing compliance which will certify that the Agreement Product was manufactured in accordance with its applicable Product Specifications and Master Specification Document. 

Section 4.03. Replacement. IDT shall replace at its own cost and expense, including reimbursement of freight and disposition costs
incurred by Sophia, Agreement Products that fail to comply with the Product Specifications. Sophia shall notify IDT of the existence and nature of any non-compliance and IDT shall have a reasonable
opportunity, not to exceed [**] from receipt of notification, to inspect such defective Agreement Product and provide Sophia with detailed written instructions to return or dispose of such defective Agreement Product. Sophia shall have no obligation
to pay for any Agreement Product that is subject to such a claim of non-compliance or defect. For purposes of clarity, Agreement Products that conform in all material respects to the Product Specifications and
when applicable the corresponding Master Specification Document, but that fail to functionally perform in Sophia’s assay, shall not be subject to replacement under this section 4.03, and the Sophia’s sole remedy shall be to reorder the
Agreement Product under the same or an amended Product Specifications with an amended Master Specification Document when applicable. 

Section 4.04. Warranty/Default Expiration Date. IDT warrants that all Agreement Products shall be delivered in compliance with the
Product Specifications and will be manufactured in accordance with their respective Master Specification Document. Unless otherwise specified in an MSD or in this Agreement, for any Agreement Product that is or contains [**], the expiration date is
[**], and for Agreement product that is or contains [**] the expiration date is [**]. The term “expiration date” is measured from the IDT delivery date, and means the date after which IDT no longer warrants that [**] will meet the
analytical specifications included on the Certificate of Analysis, when retested by IDT using analytical methods and equipment substantially identical to the original methods and equipment. The expiration date warranty is expressly conditioned on
[**]. IDT disclaims any and all other warranties, whether express or implied, regarding the design, merchantability or fitness for particular purpose of Agreement Products. 

ARTICLE 5 

AGREEMENT PRODUCT PRICING 

Section 5.01. Prices. Prices for each Agreement Product shall be agreed upon for each Agreement Product upon completion of the
corresponding Master Specification Document, and shall be incorporated into this Agreement as Exhibit C1. IDT’s acceptance of Sophia’s purchase orders and its obligations to make Commercial Products under the terms of this Agreement are
made expressly subject to the Parties agreeing to pricing, Product Specifications, the resulting Master Specification Document, and delivery schedules. 

  
 4 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 5.02. Price Changes. [**]. 

Section 5.03. “Real Cost” Price Changes. Within [**] of this Agreement, and [**], IDT shall notify
Sophia in writing of any actual net increase or decrease in IDT’s cost in producing Commercial Products during such [**] then ended. If Sophia has ordered at least [**] of the forecasted quantities of Commercial Products pursuant to 1.2 of this
Agreement, the price for Commercial Products [**]. [**]. 
 Section 5.04. “Short of Forecast” Price
Changes. If Sophia has not ordered at least [**] of the forecasted quantities during the [**] of this Agreement, IDT may [**]. 

Section 5.05. Payments. Upon delivery of Commercial Products, IDT will provide an invoice to Sophia which shall be payable by
Sophia within [**] after the date of the invoice for the Commercial Products. All payments shall be made in Euros. Unless otherwise specified, each payment under this Agreement shall be made to IDT by check to the following address: 

Integrated DNA Technologies, Inc. 

[**] 
 ARTICLE 6 

TERM AND TERMINATION 

Section 6.01. Term. This Agreement shall become effective on the Effective Date and shall have an initial term of five
(5) years. This Agreement shall automatically renew for additional one (1) year periods, unless either Party notifies the other of its desire not to renew this Agreement within [**] prior to the end of the initial term. Notwithstanding the
foregoing, Sophia shall have the right to termination this Agreement in the event the Parties are not able to agree on the price changes as set forth in Section 5.03 and 5.04 without any liability. 

Section 6.02. Termination for Breach. The Agreement may be terminated by giving written notice to take effect immediately by
either Party for failure to meet essential terms of the Agreement by the other Party, such termination entering into effect in case the Party in default is not able to remedy its failure within [**] upon written notice of such failure by the other
Party. 
 Section 6.03. Effects of Termination — Sell-off Rights. Upon termination
of the Agreement, Sophia shall have [**] from the effective date of termination to sell off the remaining Commercial Products, after which Sophia shall immediately return all Commercial Products to IDT. 

  
 5 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 7 

CONFIDENTIALITY 

Section 7.01. The Parties agree to keep confidential and proprietary and not to disclose any confidential information obtained pursuant
to the performance of their duties and obligations under this Agreement, including but not limited to, sequence information, product pricing, know how, and trade secrets for a period of [**] thereafter and will not use it other than as permitted
under this Agreement. Said information includes all information and data whether in writing or in any eye or machine-readable form and whether nominated as confidential or not. Any person performing work on behalf of one of the Parties under this
Agreement, including but not limited to employees or distributors, to the extent such work is permitted under this Agreement, shall not be considered as third party within the meaning of this Section, provided that such persons assume in writing the
same confidentiality obligation. The above obligations of confidentially shall not apply to the extent: 
 (a) Such information is general
public knowledge or, after disclosure hereunder, becomes general or public knowledge through no fault of the receiving Party; or Such information can be shown by the receiving Party by its written records to have been in its possession prior to
receipt thereof hereunder; or 
 (b) Such information is received by the receiving Party from any third party for use or disclosure without
any obligation to the disclosing Party; or 
 (c) Such information is developed independently without being based on information disclosed
hereunder; or 
 Section 7.02. The disclosure of such information is required to comply with or fulfill governmental requirements,
submissions to governmental bodies, or the securing of regulatory approvals, provided that such governmental authorities will be made aware of the confidential character of such information and that the disclosing Party will be informed by the
receiving Party of its disclosure obligation sufficiently in advance. 
 ARTICLE 8 

INDEMNITY AND LIMITATION OF LIABILITY 

Section 8.01. Product Design/Clinical Use/Compliance. The Parties hereto acknowledge that Sophia, and not IDT, has designed and
developed all Agreement Products for their use, or for their potential use in clinical or diagnostic applications. The Parties further acknowledge that IDT did not engage or otherwise contribute to, or participate in, any of the following acts of
product design or development: (i) [**], (ii) assay design and optimization, (iii) clinical trial design, implementation or reporting, (iv) establishing any clinical testing procedure or standard, (v) performing any false positive or
false negative risk analysis or mitigation, (vi) establishing any product labeling requirements, or (vii) performing any other act that is in any way related to the design of 

  
 6 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 
the clinical product or service in which the Agreement Products are used, hereafter collectively (“Product Design”). Sophia acknowledges that IDT’s obligations and responsibilities
with respect to the clinical performance of Agreement Products are expressly limited to IDT manufacturing Agreement Products in compliance in all material respects with the Product Specifications and Master Specification Document provided herein,
and all laws, rules and regulations applicable to the manufacture and shipment of Agreement Products. For further clarity, Sophia and not IDT is responsible for making the final determination of whether a compliant regarding an Agreement Product
sold by Sophia to a Sophia customer must be reported to the US FDA, China FDA (CFDA) or any other comparable foreign agency, and for otherwise complying with all FDA regulations and applicable foreign regulatory requirements pertaining to field
alerts, field actions, and/or the reporting of adverse device events, including specifically 21 CFR Part 803, regarding any Agreement Product used or sold by Sophia. 

Section 8.02. IDT Indemnification. IDT shall indemnify and hold harmless Sophia and its directors, officers, employees and
agents from and against any and all costs, claims, damages, expenses and liabilities asserted by any third party to the extent that such third party claim arises out of the delivery to Sophia of Agreement Products that fail to conform to the Product
Specifications of the Agreement Products by IDT, except to the extent such third party claim arises out of any breach of this Agreement by Sophia or the gross negligence or willful misconduct of Sophia, its directors, officers, employees or agents.

 Section 8.03. Sophia Indemnification. Sophia shall indemnify and hold harmless EDT and its directors, officers, employees and
agents from and against any and all costs, claims, damages, expenses and liabilities asserted by any third party to the extent that such third party claim arises out of or is otherwise related to Product Design, as herein defined, except to the
extent such third party claim arises out of any breach of this Agreement by IDT or the gross negligence or willful misconduct of IDT, its directors, officers, employees or agents. 

Section 8.04. LIMITATION OF LIABILITY. EXCEPT WITH RESPECT TO THE INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 8.02 AND 8.03
HEREIN, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY OTHER ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR RELIANCE DAMAGES, HOWEVER CAUSED, WHETHER FOR BREACH OF CONTRACT, NEGLIGENCE OR UNDER ANY OTHER LEGAL
THEORY, WHETHER FORESEEABLE OR NOT AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. NOTWITHSTANDING THE FOREGOING, EXCEPT WITH RESPECT TO
THE INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 8.02 AND 8.03 HEREIN, NEITHER PARTY’S TOTAL LIABILITY UNDER THIS AGREEMENT SHALL EXCEED THE TOTAL AMOUNT PAID BY SOPHIA TO IDT. 

  
 7 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 9 

INTELLECTUAL PROPERTY 

Section 9.01. Improvements. All inventions that are made directly as a result of the manufacture of Agreement Products and that
are (or that claim) improvements to Agreement Products (“Product Improvement IP”) will be owned by Sophia, notwithstanding that employees of both Parties may be involved in an invention or IDT’s or Sophia’s employees alone
are the inventors. IDT shall automatically obtain a fully-paid up, royalty-free, worldwide license, which shall be revocable upon termination or expiration of this Agreement, to the Product Improvement IP to make, have made, use (for purpose of
manufacturing the Agreement Products only), and sell Agreement Products exclusively to Sophia. Notwithstanding the foregoing, IDT shall own without obligation to Sophia, any and all inventions that are related to IDT’s general [**]
manufacturing methods, and any other invention or other form of intellectual property that is not Product Improvement IP. IDT will immediately inform Sophia of any new Product Improvement IP and will, upon Sophia’s request, support Sophia by
executing all required documentation and acts which are necessary for the transfer of such rights to Sophia. Any expenses of IDT in this regard will be reimbursed by Sophia. For clarification purposes, all feedback on the Agreement Products shall be
considered Sophia’s Product Improvement IP and shall not be used for other customers or third-party Sophias. The Product Improvement IP license herein is only for the purpose of manufacturing and providing Sophia the Agreement Products in
accordance with this Agreement. 
 Section 9.02. Suspension of Supply. IDT may immediately and indefinitely suspend the supply
of Agreement Products, if IDT has a reasonable knowledge that its supply of Agreement Products to Sophia will infringe a third-party patent or otherwise put IDT at substantial risk of becoming the subject of litigation with a third-party. In such an
event, IDT and Sophia will immediately make best efforts to redesign Agreement Products and Master Specification Documents so as to permit ongoing supply under the terms of the Agreement. 

ARTICLE 10 

MISCELLANEOUS 

Section 10.01. Dispute Resolution. The Parties recognize that disputes may from time to time arise between the Parties during the
term of this Agreement. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish
this objective, the Parties agree to follow the procedures set forth in this Section 10.01 to resolve any dispute arising under this Agreement. In the event of such a dispute between the Parties, either Party, by written notice to the other
Party, have such dispute referred to the Parties’ respective executive officers designated below or their successors, for attempted resolution by good faith negotiations within [**] after such notice is received. Said designated officers are as
follows: 

  
 8 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 For IDT : [**] 

For Sophia: [**] 
 In the event
the designated executive officers are not able to resolve such dispute after such [**] period then the Parties shall resolve such dispute by arbitration under the [**]. Three arbitrators shall be selected. IDT and Sophia shall each select one
arbitrator and the two chosen arbitrators shall select the third arbitrator, or failing agreement on the selection of the third arbitrator, [**] shall select the third arbitrator. Unless otherwise agreed by the Parties, arbitration will take place
in [**]. The fees and expenses of the arbitration panel and the cost of the arbitration (including lawyers fees) shall be borne by the Party against whom the arbitration award rules or, to the extent a Party is only partially successful, on a pro-rata- basis in proportion to the amount awarded by the arbitration panel compared to the total amount of the claim. 

Section 10.02. Notices. All notices shall be in writing mailed via certified mail, return receipt requested, courier, or facsimile
transmission addressed as follows, or to such other address as may be designated from time to time: 
  

			
	 If to IDT to:
	  	[**]
		
	 If to Sophia, to:
	  	Sophia Genetics,
		  	Rue du Centre 172,
		  	CFI-1025 Saint Sulpice,
		  	Switzerland
		
		  	Attention: [**]

 All notices, requests, consents and other communications hereunder shall be deemed to have been (a) if by
hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (b) if sent by facsimile transmission, at the time receipt has been acknowledged by electronic confirmation or otherwise, (c) if
sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (d) if sent by certified mail, on the first business day following the day such mailing is made. 

Section 10.03. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of England, without
regard to the application of principles of conflicts of law. 
 Section 10.04. Binding Effect. This Agreement shall be binding
upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 

  
 9 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 10.05. Headings. Section and subsection headings are inserted for
convenience of reference only and do not form a part of this Agreement. 
 Section 10.06. Counterparts. This Agreement may be
executed simultaneously in two or more counterparts, each of which shall be deemed an original. 
 Section 10.07. Amendment;
Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or
failure of any Party at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by any Party of any condition or of the breach of any term contained in
this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

Section 10.08. Independent Contractors; No Agency or Partnership. The relationship between the IDT and Sophia is that of
independent contractors. Nothing contained in this Agreement shall give either Party the right to bind the other, or be deemed to constitute the Parties as agents for the other or as partners with each other or any third party. 

Section 10.09. Assignment and Successors. This Agreement may not be assigned by either Party without the consent of the other
Party, except that either Party may assign this Agreement and its rights, obligations and interests hereunder, in whole or in part, to any of its Affiliates and/or to any successor to substantially all of that Party’s business to which this
Agreement relates. 
 Section 10.10. Force Majeure. Neither IDT nor Sophia shall be liable for failure of or delay in performing
obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of IDT or Sophia. In event of such force majeure, the
Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

Section 10.11. Interpretation. The Parties hereto acknowledge and agree that: (i) each Party and its counsel reviewed and
negotiated the terms and provisions of this Agreement and have contributed to its revision; and (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation
of this Agreement. 
 Section 10.12. Integration; Severability. This Agreement is the sole agreement with respect to the subject
matter hereof and supersedes all other agreements and understandings between the Parties with respect to the same. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. 

  
 10 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

									
	Integrated DNA Technologies, Inc.	  		  	Sophia
					
	By:	  	 /s/ Todd E. McManus
	  		  	By:	  	 /s/ Jurgi Camblong

		  	Name:    Todd E. McManus	  		  		  	Name:    Jurgi Camblong
		  	Title:      General Counsel	  		  		  	Title:      CEO
		  	Date:      October 18, 2018	  	        	  		  	Date:       October 19, 2018
					
		  		  		  	By:	  	 /s/ Valentin Matillon

		  		  		  		  	Name:    Valentin Matillon
		  		  		  		  	Title:      CFO
		  		  		  		  	Date:      October 19, 2018

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS S.A. (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA treats as private or confidential. 

 EXHIBIT A 

MASTER SPECIFICATION DOCUMENT 

(MSD-Sophia-001; Title) 

For Discussion Purposes Only 
 For general
specifications regarding the IDT Exome Research Panel, see: 

https://www.idtdna.com/pages/products/nextgen/target-capture/xgen-lockdown-panels/xgen-exome-panel  

For general specifications for additional panels, see: www.idtdna.com 

  
 A-1 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 EXHIBIT B 

CONTROLLED MSDS 
 [**] 

  
 B-1 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 EXHIBIT C1 

COMMERCIAL PRODUCT PRICING 

Additional Terms and Conditions: 

Product pricing for the IDT Exome Research Panels, and all other IDT Lockdown NGS panels are made subject to the following terms, conditions,
and restrictions, and all sales of such products under this Agreement are made subject expressly to the following: 
  

	1.	 Authorized Use In Sophia Products/Not for Resale. Sophia is expressly permitted to incorporate
the Commercial Products into Sophia products and services to be sold to Sophia’s Authorized Customers; provided however, that (i) a “Sophia Authorized Customer” shall mean and be expressly limited to a third party in any country,
which customer has (ii) subscribed to, or otherwise contracted with Sophia to use its bioinformatics softwares and data analysis solutions, and (iii) the Commercial Products must be incorporated into a Sophia branded value-added product or
service, and may not be resold as a separate standalone product without IDT’s express written consent. 

  

	2.	 Regulatory Approval. Without limiting the scope of 7.1 herein, as between the parties, Sophia,
and not IDT, shall be responsible for: (i) satisfying any and all regulatory requirements, (ii) corresponding with or in response to regulators and/or registrars, and (iii) applying for an obtaining any certifications required for the
use of the Commercial Products in Sophia products, and/or sold to Sophia’s Authorized Customers. 

  

	3.	 Customer Support. Customer support shall be organized in three levels of support:

 [**] 

  
 C1-1 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 EXHIBIT C2 

RESEARCH PRODUCT PRICING 

[**] 

  
 C2-1 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 EXHIBIT D 

DEFINITIONS 
 For the
purpose of this Agreement, the terms set forth herein shall be defined as follows: 
 “Agreement Products” shall mean
(i) Commercial Products and (ii) Research Products. 
 “Affiliate” shall mean any company, corporation,
partnership or other business entity which directly or indirectly controls or is controlled by, or is under common control with Sophia or IDT. For the purpose of this Agreement the term “control” (including the terms “controlled
by” and “under common control with”) shall mean the possession of the power to direct or cause the direction of the management or policies of the company, corporation, partnership or business entity involved, whether through the
ownership of at least 50% (in words: fifty percent), by contract or otherwise. 
 “Commercial Products” shall mean [**]
ordered for use in or as commercial products to be marketed and sold by Sophia, and which are defined and governed by a Master Specification Document. 

“End User” shall mean a purchaser of Agreement Products or a distributor of Agreement Products. 

“Master Specification Document (MSD)” shall mean a comprehensive controlled document, approved by Sophia, that defines the
procedures and methods by which IDT will manufacture Commercial Products (in a form similar to the MSD attached hereto as Exhibit A), and that can be changed only with the prior notice and approval of Sophia. Whenever possible, Commercial
Products will be organized into product classes that have product specifications and process requirements consistent with the MSD groupings included in Exhibit B, as amended from time-to-time. 

“Party” shall mean either Sophia or IDT individually, as the context requires. 

“Parties” shall mean both Sophia and IDT jointly. 

“Product Specifications” shall mean analytical specifications, sequences, formulation specifications, and other product
requirements as defined by Sophia for each individual Agreement Products, and with which IDT will develop a corresponding Master Specification Document, if applicable. 

  
 D-1 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 “Research Products” shall mean products that are ordered via the website
(www.idtdna.com) and that are manufactured, and delivered according to IDT’s standard specifications, procedures and deliverables. 

  
 D-2 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 APPENDIX I 

[**] 

  
 Ap.-1 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 [**] 

  
 Ap.-2 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 [**] 

  
 Ap.-3 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]